HER2 Support Group Forums - View Single Post

JohnL · 05-14-2006, 03:31 AM

The proportionate benefit for small tumours is the same as for others. The HERA study included a large sample of small tumour node-negative patients.

Thus even with a post-chemo relapse in the 10% to 15% range, the gain in halving that is well worth taking given that the risks associated with hereceptin are quite low if your wife is otherwise healthy.

My wife (45) with a 1.4 cm tumour N0 had FEC(100) x 2 and Taxotere x 4 plus Herceptin for a year. So a bit more of an aggressive approach taken, largely on the basis of her relatively young age.

Good luck

John L

05-14-2006, 03:31 AM	#7
JohnL Member Join Date: Sep 2005 Location: London, England Posts: 24	The proportionate benefit for small tumours is the same as for others. The HERA study included a large sample of small tumour node-negative patients. Thus even with a post-chemo relapse in the 10% to 15% range, the gain in halving that is well worth taking given that the risks associated with hereceptin are quite low if your wife is otherwise healthy. My wife (45) with a 1.4 cm tumour N0 had FEC(100) x 2 and Taxotere x 4 plus Herceptin for a year. So a bit more of an aggressive approach taken, largely on the basis of her relatively young age. Good luck John L